This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Nature medicine, 6(10), 1167-75
Citation
Bielekova, B; Goodwin, B; Richert, N; Cortese, I; Kondo, T; Afshar, G; Gran, B; Eaton, J; Antel, J; Frank, J A; McFarland, H F; Martin, R. (2000). Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.. Nature medicine, 6(10), 1167-75.